Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

est discomfort (one percent) or chest pain (0 percent), were rare and comparable to placebo. There were no decreases in lung function, as measured by spirometry, between the active and placebo groups.

"These sub-analyses further heighten our enthusiasm for LEVADEX and its potential to help the many patients who suffer from the debilitating effects of migraine, including the potential to provide benefit to a number of significant subpopulations of migraine patients who are not well served by currently available therapies," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to continuing development of LEVADEX and initiating a confirmatory Phase 3 trial in the first quarter of 2010."

LEVADEX data are being presented in a late-breaking oral platform presentation titled "LEVADEX(TM), a novel orally inhaled treatment for acute migraine: efficacy and tolerability results of a Phase 3 study" on Saturday, September 12, 2009 at the 14th Congress of the International Headache Society in Philadelphia, PA by clinical trial investigator Stephen Silberstein, M.D., F.A.C.P., director of the Jefferson Headache Center, and professor in the Department of Neurology at Jefferson Medical College of Thomas Jefferson University. In addition, three poster presentations titled 1) "Efficacy and tolerability of MAP0004, a novel inhaled therapy, in treating acute migraine", 2) "Efficacy evaluation of LEVADEX(TM) (previously MAP0004) in treating resistant migraine including migraine with allodynia, migraine treated late in its cycle, morning migraine and disabling migraine" and 3) "Efficacy evaluation of LEVADEX(TM) (previously MAP0004) in treating a broad spectrum of acute migraine attacks including patients using triptans and patients not using triptans" will be available for review at the conference.

Webcast Information

MAP Pharmaceuticals will host a webcast on
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Glenmark ... Glenmark Pharmaceuticals Limited India (GPL), announces the discovery ... novel clinical development candidate, GBR 1302, a HER2xCD3 ... by the Glenmark Biologics Research Centre located in ... 1302 is based on Glenmark,s innovative BEAT antibody ...
(Date:8/19/2014)... Ala. , Aug. 19, 2014  The Alabama Supreme ... that patients can sue drug makers who mislead doctors into ... harmful side‑effects.  The case is Weeks v. Wyeth, and the ... makers in that same case last year. Heninger Garrison Davis ... represent the patient in the case, Danny Weeks . ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive ... medical device company, announced today that Mitsubishi Corporation ... and robotic visualization system in Japan ... sale in Japan in the ... also the exclusive distributor for Karl Storz GMBH & ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... 2011 Quest Diagnostics Incorporated (NYSE: DGX), the world,s ... today that Spark Acquisition Corporation, its wholly owned subsidiary ... outstanding shares of common stock of Celera Corporation (NASDAQ: ... has been extended to 5:00 p.m., New York City ...
... May 9, 2011 In honor of National ... launch and the grand opening of its home health and ... best in ecommerce and printed in-waiting room catalog solutions for ... those currently undergoing treatment and the 220,000 women who will ...
Cached Medicine Technology:Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera 2Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera 3Someone With Opens its Doors to Create Online Marketplace for Breast Cancer Products and Services 2Someone With Opens its Doors to Create Online Marketplace for Breast Cancer Products and Services 3Someone With Opens its Doors to Create Online Marketplace for Breast Cancer Products and Services 4
(Date:8/20/2014)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies ... for its annual fall conference, WEDI-Con 2014: The ... will take place at the HYATT Regency in ... diverse cross-section of payers, providers, government regulators, industry ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... NC (PRWEB) August 20, 2014 Doctors at ... way to wipe out mesothelioma in laboratory mice by injecting ... has just posted details of the study on its website. ... , Scientists with Hong Kong University’s AIDS Institute of Microbiology ... protein 1” or PD-1. By altering DNA, the vaccine is ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... Office of Naval Research are working on using virtual ... Disorder (PTSD). //, ,In this research, scientists are ... from PTSD to go through the similar experiences they ... the traumatic experience that had left them unable to ...
... the declining numbers of infants in the Middle East ... first six months of their lives.//, ,"Several high-income ... Qatar, Oman, the UAE and Saudi Arabia maintain patterns ... below 35 percent," Unicef said in a statement released ...
... very active leisure time can reduce the chances of having ... from National Public Health Institute in Helsinki, Finland, had reported ... Heart Association., ,Researchers had looked into the data provided ... 25 to 64 years, all of them healthy and without ...
... the University of Arkansas, Worcester Polytechnic Institute //and other ... to examine the fossils of our ancestors’ teeth to ... and why. ,By comparing teeth from two species ... researchers confirm previous evidence that A. africanus ate more ...
... change in the genetic constitution is what makes each ... is unraveled, then health care can be individualized according ... same genetic code, how those genes express themselves at ... medicines and dietary advice. According to a recent study, ...
... Nebraska, was slated for a slow but sure death, weighing in ... or even turn over in bed. , ,Deuel is now ... than 200 kg after undergoing an operation that is becoming increasingly ... opera singer, Deborah Voigt, also lost 50 kg after she underwent ...
Cached Medicine News:Health News:Breastfeeding Decline In Middle East Worries UN 2Health News:Physical Activity During Leisure Can Reduce Risk Of Stroke 2Health News:Scientists Develop New Technology To Find About Human Ancestors’ Teet 2Health News:Learning Just How Different We Are 2Health News:Obesity better handled with gastric bypass surgery 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
Medicine Products: